title: Pioglitazone and risk of bladder cancer: clarification of the design of the French study. Reply to Perez AT [letter].
authors.forename: A
authors.initials: A
authors.lastname: Neumann
authors.forename: A
authors.initials: A
authors.lastname: Weill
authors.forename: P
authors.initials: P
authors.lastname: Ricordeau
authors.forename: J P
authors.initials: JP
authors.lastname: Fagot
authors.forename: F
authors.initials: F
authors.lastname: Alla
authors.forename: H
authors.initials: H
authors.lastname: Allemand
mesh_terms: D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy*; D005260:Female; D006801:Humans; D007004:Hypoglycemic Agents / Q000009:adverse effects*; D008297:Male; D045162:Thiazolidinediones / Q000009:adverse effects*; D001749:Urinary Bladder Neoplasms / Q000139:chemically induced*
chemical_list: D007004:Hypoglycemic Agents; D045162:Thiazolidinediones